Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells

Antibodies are thought to exert antiviral activities by blocking viral entry into cells and/or accelerating viral clearance from circulation. In particular, antibodies to hepatitis B virus (HBV) surface antigen (HBsAg) confer protection, by binding circulating virus. Here, we used mathematical modeling to gain information about viral dynamics during and after single or multiple infusions of a combination of two human monoclonal anti‐HBs (HepeX‐B) antibodies in patients with chronic hepatitis B. The antibody HBV‐17 recognizes a conformational epitope, whereas antibody HBV‐19 recognizes a linear epitope on the HBsAg. The kinetic profiles of the decline of serum HBV DNA and HBsAg revealed partial blocking of virion release from infected cells as a new antiviral mechanism, in addition to acceleration of HBV clearance from the circulation. We then replicated this approach in vitro, using cells secreting HBsAg, and compared the prediction of the mathematical modeling obtained from the in vivo kinetics. In vitro, HepeX‐B treatment of HBsAg‐producing cells showed cellular uptake of antibodies, resulting in intracellular accumulation of viral particles. Blocking of HBsAg secretion also continued after HepeX‐B was removed from the cell culture supernatants. Conclusion: These results identify a novel antiviral mechanism of antibodies to HBsAg (anti‐HBs) involving prolonged blocking of the HBV and HBsAg subviral particles release from infected cells. This may have implications in designing new therapies for patients with chronic HBV infection and may also be relevant in other viral infections. (HEPATOLOGY 2010;)

[1]  E W Geddes,et al.  Establishment of a continuously growing cell line from primary carcinoma of the liver. , 1976, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[2]  Ivan Damjanov,et al.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line , 1979, Nature.

[3]  A. Zuckerman,et al.  Hepatitis B surface antigen produced by a human hepatoma cell line , 1979, Nature.

[4]  R. Fujinami,et al.  Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell , 1979, Nature.

[5]  P. Marion,et al.  Polypeptides of hepatitis B virus surface antigen produced by a hepatoma cell line , 1979, Journal of virology.

[6]  R H Purcell,et al.  PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity , 1980, Infection and immunity.

[7]  A. Zuckerman,et al.  Nondetection of infectious hepatitis B virus in a human hepatoma cell line producing hepatitis B surface antigen. , 1981, Intervirology.

[8]  E. Wimmer,et al.  Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies , 1983, Journal of virology.

[9]  R. Tedder,et al.  Production of monoclonal antibodies to hepatitis B surface and core antigens, and use in the detection of viral antigens in liver biopsies , 1983, Journal of Hygiene.

[10]  T. Crawford,et al.  Antibody-mediated clearance of alphavirus infection from neurons. , 1991, Science.

[11]  K. Koike,et al.  The serology of chronic hepatitis B infection revisited. , 1993, The Journal of clinical investigation.

[12]  M. Mazanec,et al.  Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies , 1995, Journal of virology.

[13]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[14]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[15]  Lubin,et al.  Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system , 1998, Immunology.

[16]  Damien Fleury,et al.  A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site , 1999, Nature Structural Biology.

[17]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[18]  D. Samuel,et al.  Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review , 2000, Hepatology.

[19]  K. Shimotohno,et al.  Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen , 2000, Hepatology.

[20]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[21]  E. Galun,et al.  Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV‐Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees , 2000, Hepatology.

[22]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[23]  H. Hsu,et al.  Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination , 2001, Annals of Internal Medicine.

[24]  B. Portmann,et al.  Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. , 2001, Journal of hepatology.

[25]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[26]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[27]  P. van Oostveldt,et al.  Antibody-induced internalization of viral glycoproteins in pseudorabies virus-infected monocytes and role of the cytoskeleton: a confocal study. , 2002, Veterinary microbiology.

[28]  A. Neumann,et al.  The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. , 2002, Journal of hepatology.

[29]  E. Keeffe,et al.  Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties , 2002, Hepatology.

[30]  Roger Williams,et al.  Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and Virions , 2003, Journal of Virology.

[31]  R. Tedder,et al.  A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of 'second loop' immune escape. , 2003, The Journal of general virology.

[32]  D. Samuel,et al.  HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.

[33]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[34]  Raimund J. Ober,et al.  Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1 , 2004, The Journal of Immunology.

[35]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[36]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[37]  A. Neumann.  Hepatitis B viral kinetics: A dynamic puzzle still to be resolved , 2005, Hepatology.

[38]  A. Hatzakis,et al.  A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative , 2005, Hepatology.

[39]  Rolf M. Zinkernagel,et al.  Antiviral antibody responses: the two extremes of a wide spectrum , 2006, Nature Reviews Immunology.